On-target, off-tumor toxicity is commonly observed in patients with B-cell malignancies after CAR-T therapy, as CAR-T cell targets (CD19, CD20 and/or CD22) are expressed in both normal and malignant B cells. Here, CD19 is linked to neoplasm.